Ripk3 signaling regulates HSCs during stress and represses radiation-induced leukemia in mice

Lei Zhang
*Loyola University Health System*

Huacheng Luo
*Penn State College of Medicine*

Hong Min Ni
*University of Kansas Medical Center*

Shanhui Liu
*Loyola University Health System*

Hongyun Xing
*Loyola University Health System*

*See next page for additional authors*

Follow this and additional works at: https://ecommons.luc.edu/biology_facpubs

**Recommended Citation**

Zhang, Lei; Luo, Huacheng; Ni, Hong Min; Liu, Shanhui; Xing, Hongyun; Zhang, Jun; Sellin, Mark; Breslin, Peter S.J.; Wei, Wei; Denning, Mitchell F.; Small, William; Ding, Wen Xing; Huang, Suming; and Zhang, Jiwang. Ripk3 signaling regulates HSCs during stress and represses radiation-induced leukemia in mice. *Stem Cell Reports*, 17, 6: 1428-1441, 2022. Retrieved from Loyola eCommons, Biology: Faculty Publications and Other Works, http://dx.doi.org/10.1016/j.stemcr.2022.04.009

This work is licensed under a Creative Commons Attribution 4.0 International License.
Ripk3 signaling regulates HSCs during stress and represses radiation-induced leukemia in mice

Lei Zhang,1,2,9 Huacheng Luo,3,9 Hong-Min Ni,4 Shanhui Liu,1 Hongyun Xing,1 Jun Zhang,5 Mark Sellin,1 Peter Breslin, S.J.,1,6 Wei Wei,1 Mitchell F. Denning,1 William Small, Jr.,7 Wen-Xing Ding,1 Suming Huang,3,* and Jiawang Zhang1,7,8,*
1Department of Cancer Biology, Oncology Research Institute, Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, IL 60153, USA
2Cyrus Tang Hematology Center, Collaborative Innovation Center of Hematology, National Clinical Research Center for Hematologic Diseases, Soochow University, Suzhou 215123, China
3Department of Pediatrics, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA
4Department of Pharmaceutics, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City, KS 66160, USA
5Department of Biology, College of Life Sciences, Shanghai Normal University, Shanghai 200234, People’s Republic of China
6Departments of Molecular/Cellular Physiology and Biology, Loyola University Chicago, Chicago, IL 60660, USA
7Department of Radiation Oncology, Loyola University Medical Center, Maywood, IL 60153, USA
8Department of Pathology, Loyola University Medical Center, Maywood, IL 60153, USA
9These authors contributed equally
*Correspondence: shuang4@pennstatehealth.psu.edu (S.H.), jzhang@luc.edu (J.Z.)
https://doi.org/10.1016/j.stemcr.2022.04.009

SUMMARY

Receptor-interacting protein kinase 3 (Ripk3) is one of the critical mediators of inflammatory cytokine-stimulated signaling. Here we show that Ripk3 signaling selectively regulates both the number and the function of hematopoietic stem cells (HSCs) during stress conditions. Ripk3 signaling is not required for normal homeostatic hematopoiesis. However, in response to serial transplantation, inactivation of Ripk3 signaling prevents stress-induced HSC exhaustion and functional HSC attenuation, while in response to fractionated low doses of ionizing radiation (IR), inactivation of Ripk3 signaling accelerates leukemia/lymphoma development. In both situations, Ripk3 signaling is primarily stimulated by tumor necrosis factor-α. Activated Ripk3 signaling promotes the elimination of HSCs during serial transplantation and pre-leukemia stem cells (pre-LSCs) during fractionated IR by inducing Mlkl-dependent necroptosis. Activated Ripk3 signaling also attenuates HSC functioning and represses a pre-LSC-to-LSC transformation by promoting Mlkl-independent senescence. Furthermore, we demonstrate that Ripk3 signaling induces senescence in HSCs and pre-LSCs by attenuating ISR-mediated mitochondrial quality control.

INTRODUCTION

Receptor-interacting protein kinase 3 (Ripk3) is a serine/threonine protein kinase that induces necroptosis, a type of programmed cellular necrosis, by phosphorylation activation of mixed-lineage kinase domain-like protein (Mlkl). In most types of tissue cells, Ripk3 activation is stimulated by tumor necrosis factor-α (Tnfr-α) through induction of the formation of a Ripk1 and Ripk3 complex (a necroptosome) via receptor-interacting protein kinase homotypic interaction motif (RHIM) domain-mediated Ripk1 and Ripk3 interaction (Van Herreweghe et al., 2010). Ripk3 activation can also be stimulated by interferon (Ifn), interleukin-1β (IL-1β), toll-like receptor (Tlr) signaling, or viral infection by inducing the interaction of Ripk3 with other RHIM proteins, including DNA-dependent activator of Ifn-regulatory factors (Dai), also known as Zbp1, and Tir-domain-containing adapter-inducing Ifn-β (Trif), also known as Ticam1 (Brault et al., 2018; Kaiser et al., 2013; Schock et al., 2017; Upton et al., 2012). Activated Ripk3 phosphorylates Mlkl, which promotes oligomerization and plasma membrane localization of Mlkl, inducing membrane permeabilization and necroptosis. In addition, Ripk3 can also induce reactive oxygen species (ROS) production, probably by phosphorylating mitochondrial proteins such as Pdc-E3, Pygl, Glul, and Gludl, and cytokine production by stimulating the activation of NF-κB and inflammasomes (Kang et al., 2015; Moriwaki et al., 2014; Wang et al., 2014).

Studies have suggested that Ripk3 signaling plays critical roles in the pathogenesis of many hematopoietic disorders (Hockendorf et al., 2016; Wagner et al., 2019; Xin et al., 2016a, 2016b). Some leukemia-related mutations induce the activation of Ripk3 signaling in hematopoietic cells (Hockendorf et al., 2016; Lee et al., 2018). Ripk3/Mlkl-mediated necroptosis is detected in bone marrow (BM) samples from patients with aplastic anemia (AA) and myelodysplastic syndromes (MDS) (Wagner et al., 2019; Xin et al., 2016a). Inactivation of Ripk3 signaling prevents T cell activation and AA development in a Tak1-mutant mouse model (Xin et al., 2016a). In acute myeloid leukemia (AML), Ripk3 signaling might be epigenetically repressed in leukemic cells isolated from a subgroup of AML patients such as AML with RUNX1-ETO or FLT3-ITD mutations (Hockendorf et al., 2016). Ripk3 signaling represses the development of such sub-types of AML by stimulating Mlkl-mediated necroptosis and IL-1β-induced differentiation of pre-leukemia stem cells.
(pre-LSCs) as demonstrated in mouse models (Hockendorf et al., 2016). However, in HOXA-expressing AML, such as AML with NPM1 or MLL gene mutations, RIPK3 signaling is activated, which promotes such AML development by repressing the differentiation of leukemic cells via inhibition of JAK1-STAT1 signaling (Xin et al., 2016b). However, the role of Ripk3 signaling in the regulation of normal and stress hematopoiesis has not been studied.

Exposure to ionizing radiation (IR) induces both acute tissue damage and chronic long-term residual damage (LT-RD) in the body. Among all tissues, BM is the most sensitive to both IR-induced acute tissue damage and LT-RD. After IR, BM failure and reduction of peripheral blood (PB) cell counts often occur within days due to the massive death of hematopoietic stem cells (HSCs) and hematopoietic progenitor cells (HPCs). Compared with proliferative HPCs, quiescent HSCs are relatively resistant to IR-induced death. However, due to the quiescent cell-cycle status and lower fidelity of DNA repair in this instance, some HSCs cannot fully repair chromosomal damage and thus become senescent (a permanent cell-cycle-arrested status). Such residually damaged HSCs cause LT-RD in BM as demonstrated by abnormal dysplastic hematopoiesis in most IR victims, followed by increased risk for the development of leukemia (Carbonneau et al., 2012; Gutierrez-Martinez et al., 2018; Shao et al., 2010, 2014). Thus, IR exposure is an established cause of BM failure and leukemia.

In addition to directly inducing damage in DNA, IR also induces the generation of ROS and subsequent secondary reactive pro-inflammatory processes and innate immune responses (Cadet and Davies, 2017; Kim et al., 2014; Mavragani et al., 2016). All these are believed to contribute to both acute BM damage and LT-RD. However, the molecular mechanism by which IR induces acute BM damage, LT-RD, and leukemia pathogenesis has still not been fully elucidated (Wang et al., 2010). Most previous studies suggested that the acute BM damage is primarily mediated by IR-induced ROS production and DNA damage through the activation of p53-Puma-dependent apoptosis in proliferative HPCs, while LT-RD is mediated by long-lived free radicals and pro-inflammatory cytokines/chemokines, which induce mitochondrial damage and senescence in quiescent HSCs. The accumulation of additional genetic mutations and escape from senescence are the potential mechanisms underlying the development of cancer (Palacio et al., 2017).

By comparing hematopoiesis among wild-type (WT), Ripk3-knockout (Ripk3−/−), Tnfα receptor knockout (Tnfr−/−), and Mlkl-knockout (Mlkl−/−) mice under normal homeostatic conditions, serial transplantation-related stress conditions, and IR-stress conditions, we demonstrate here a specific role for Ripk3 signaling in the regulation of both the number and the function of HSCs in the stressed tissue setting.

RESULTS

Normal hematopoiesis in Ripk3−/− mice and Mlkl−/− mice during homeostasis

Ripk3−/− and Mlkl−/− mice were maintained in a healthy condition without any signs of disease to a minimum age of 1.5 years in a germ-free barrier facility. White blood cell (WBC) counts, hemoglobin (Hb) concentration, platelet (Plt) numbers, and lymphocyte/myeloid cell ratio in PB were comparable among Ripk3−/− mice, Mlkl−/− mice, and their age/gender-matched WT mice (Figure 1).

In the BM, the percentages and absolute numbers of Lin−Sca1+c-kit+ (LSK) and Lin−Sca1−c-kit+ (LK) populations were also comparable among WT, Ripk3−/−, and Mlkl−/− mice. Furthermore, HSCs and multipotent progenitor 1 (MPP1), MPP2, MPP3, and MPP4 cells within the LSK population, and common myeloid progenitors (CMPs), granulocyte-monocyte progenitors (GMPs), megakaryocyte/erythrocyte progenitors (MEPs), megakaryocyte progenitors (MKPs), and pre-colony forming unit-erythroid (pre-CFU-E) and CFU-E cells within the LK-myeloid progenitors (LK-MPs), as well as common lymphocyte progenitors (CLPs), were also comparable among WT, Ripk3−/−, and Mlkl−/− mice (Figures 1, S1, and S2).

Inactivation of Ripk3 signaling prevents Mlkl-mediated HSC exhaustion and ROS-p38-mediated senescence during serial transplantation

Ripk3-Mlkl signaling was not activated in HSCs under homeostatic conditions but was induced during serial transplantation in BM mononucleated cells (MNCs) as shown by western blotting and in LSK-HSCPs (HSCs + MPPs) as demonstrated by flow cytometric assay (Figures 2 A–2C). To study the role of Ripk3-Mlkl signaling in the regulation of HSC self-renewal, we first conducted serial transplantation experiments without using competitor BM cells. BM and PB of the recipient mice were analyzed 4 months after each round of transplantation. We found that the percentages and absolute numbers of HSCs, MPPs, and LK cells (including CMP, GMP, MEP, MKP, pre-CFU-E, and CFU-E) were comparable among mice that had received Ripk3−/−, Mlkl−/−, and WT BM cells in the first and second transplantations (Figure 2D and data not shown). However, during the third transplantation, although the percentages and absolute numbers of MPPs and LK cells were still comparable in all recipient mice regardless of the genotype of BM cells transplanted, the numbers of HSCs were significantly reduced in mice that had received WT BM cells compared with mice receiving either Ripk3−/− or Mlkl−/− BM cells (Figures 2D–2F, S3A, and S3B). These data suggest that inactivation of Ripk3-Mlkl signaling selectively prevents the loss of HSCs during serial transplantation. Interestingly, when Ripk3−/−, Mlkl−/−, and WT BM cells were collected
from third transplantation recipients for CFU assay and competitive transplantation study, we found that, despite the comparable CFU capacity of BM cells among all genotypes (Figure 2G), only Ripk3−/− BM cells were able to maintain their competitive hematopoietic reconstitutive capacity (CHRC; as demonstrated by percentage of donor-derived cells in PB), while the CHRC was significantly reduced in both Mlkl−/− and WT BM cells (Figure 2H). In addition, significant myeloid-biased hematopoiesis was observed in Mlkl−/− and WT BM cells but not in Ripk3−/− BM cells (Figure S3C). This study suggests that Ripk3 signaling impairs HSC function during serial transplantation through an Mlkl-independent mechanism. Consistent with this observation, in a serial competitive transplantation study we also found that the CHRCs of Ripk3−/−, Mlkl−/−, and WT BM cells were comparable for the first and second transplantations. However, upon third transplantation, a significant reduction in CHRC was observed in both Mlkl−/− and WT BM cells, but not in Ripk3−/− BM cells (Figure S3D).

Ripk3 deletion promotes IR-induced leukemia/lymphoma development in mice

Fractionated low-dosage IR (1.75 Gy weekly × 4) induces thymomas (lymphomas in the thymus gland) in WT mice. To study the role of Ripk3-Mlkl signaling in IR-induced leukemia/lymphoma development, we treated WT, Ripk3−/−, and Mlkl−/− mice with 1.75 Gy × 4 IR and monitored for disease development and mouse survival.
Figure 2. Ripk3 selectively regulates number and function of HSCs during serial transplantation in Mlkl-dependent and -independent manners, respectively

(A) Serial transplantation and analysis schedule. TP0 represents non-transplanted control. TP1, TP2, and TP3 indicate first, second, and third transplantations, respectively. "4ms" represents 4 months post-transplantation.

(B and C) BM MNCs were collected from recipient mice 4 months post-transplantation for each transplantation cycle. Activation of Ripk3-Mlkl signaling in BM MNCs (B) and LSK cells (C) was examined by western blotting and flow cytometric assays, respectively. For flow cytometric analysis, Ripk3−/− LSK cells were always used as a negative control to set up the flow cytometer in order to make the data consistent in all of the experiments.

(D) Representative flow cytometric data for HSCs and MPPs among CD45.2+ BM MNCs from second and third transplantation recipients of the indicated genotypes of donors.

(E and F) Absolute numbers of LK cells and LSK cells (E) as well as HSCs and MPPs (F) in the BM from third transplantation recipients of the indicated donor genotypes.

(G–L) BM MNCs were collected from third transplantation recipients of the indicated genotypes of donors. The cells were seeded into methylcellulose medium for CFU-C assay. The numbers of colonies were counted after 7 days of culturing (G). Cells were mixed with equal numbers of competitor BM cells for competitive transplantation study. The CHRC of the donor cells was analyzed 4 months after transplantation by examining the percentage of donor-derived cells (CD45.2+) in PB (H). ROS levels (I), p-p38 Mapk levels (J), and senescence (K) in LSK cells were examined by dichlorofluorescin diacetate (DCFDA), p-p38 antibody, and 5-Dodecanoylaminofluorescein Di-B-D-Galactopyranoside (C12GFDG) staining, respectively, followed by flow cytometric analysis. Data in (C), (I), (J), and (K) show one of the three biological triplicate experiments. "Iso" stands for isoform control. The expression of the indicated genes in LSK cells of the indicated genotypes was examined by qRT-PCR assay and normalized to the levels of the same gene in LSK cells isolated from non-transplanted WT mice (L). *p < 0.05 and **p < 0.01, compared with WT group or TP0 group. &p < 0.05, compared with Ripk3−/− group.
Most (77%, 17/22) of the Ripk3−/− mice developed acute T lymphoblastic leukemia (T-ALL) and died within 200 days, while the remaining Ripk3−/− mice developed a mixture of T-ALL/thymoma and died within 250 days (Figure 3A). T-ALL was diagnosed as >30% CD8+CD3+ T lymphoblasts in BM and PB (Figures 3B and 3C), as well as liver and kidney infiltration of lymphoblasts (Figures 3D–3G). In addition, T-ALL cells collected from BM or spleens of the mice were able to generate the same type of T-ALL in recipient mice upon transplantation (Figure 3H). However, 36.8% (7/19) of WT mice and 76.2% (16/21) of Mlkl−/− mice died of thymoma within 360 days (Figures 3A and 3I). Mlkl deletion only slightly promoted the development of IR-induced thymoma. These data suggest that Ripk3 signaling represses T-ALL development and delays the development of thymomas primarily through an Mlkl-independent mechanism. Because the lymphoblasts collected from both T-ALL and thymomic mice were phenotypically the same (CD8+CD3+), we speculate that the T-ALL and thymoma might be the same type of disease.

Ripk3-Mlkl signaling inactivation prevents low-dose IR-induced HSC exhaustion

To study the mechanism by which Ripk3 signaling represses T-ALL development, we compared IR-induced DNA damage repair in HSCs isolated from WT, Ripk3−/−, and Mlkl−/− mice. As expected, a significantly increased percentage of γ-H2A.X+ cells and greater numbers of γ-H2A.X+ foci/cell were detected among all three genotypes of LSKs by 2 h after IR. Both the percentages of γ-H2A.X+ cells and the numbers of γ-H2A.X+ foci/cell were reduced to levels slightly higher than basal at 48 h post-IR. No significant differences were observed among all three genotypes of mice, suggesting that inactivation of Ripk3-Mlkl signaling did not affect DNA damage repair in HSCs (Figures 4A and 4B).

We then compared the numbers of HPCs and HSCs among WT, Ripk3−/−, and Mlkl−/− mice 1 month after 1.75 Gy X 4 IR. Although LK-1Ps, LSKs, and MPPs were comparable among all three genotypes of mice, a significant reduction in HSCs was observed in WT mice, suggesting that Ripk3 signaling and consequent Mlkl-mediated...
necroptosis promotes the loss of HSCs induced by low-dose IR (Figures 4C, 4D, and S4A–S4C). In the chimeric transplantation model (we used a 1:1 ratio of WT and Ripk3–/–/C0–/–/C0 BM cells here), 1.75 Gy IR treatment could reduce only the number of WT HSCs and not Ripk3–/–/C0–/–/C0 HSCs, suggesting a cell-autonomous role for Ripk3 signaling in stress-induced HSC depletion (Figure S4D).

Detailed analysis demonstrated that in WT mice, low-dose IR induced the activation of Ripk3 signaling as early as 2 weeks after the first IR in BM MNCs as shown by increased levels of p-Ripk3 and p-Mlkl (Figure 4E), as well as in LSK-HSPCs (Figure 4F) and HSCs (Figure S4E) as shown by increased levels of p-Ripk3. The activation of Ripk3 signaling was correlated with increased levels of Tnf-α in PB (Figure 4G), which was followed by the reduction in HSCs as early as the third week after the first exposure to IR (Figure 4H). Interestingly, Tnf-α levels were also elevated in the PB of IR-treated Ripk3–/– mice (Figure 4G); however, p-Mlkl levels were not increased in BM MNCs of IR-treated Ripk3–/– mice (data not shown). This suggests that IR induces Ripk3-independent Tnf-α production but a Ripk3-dependent activation of Mlkl signaling. In addition, 1.75 Gy X-ray weekly failed to induce the activation of Ripk3 in HSCs in Tnfr1–/–/C0–/– mice (Figure S5A). As was the case with Ripk3–/– mice (Figure 4H), significantly more HSCs were retained in Tnfr1–/–/C0–/– mice compared with WT mice following 1.75 Gy X-ray treatment. Finally, IR-induced leukemia development was significantly accelerated in

**Figure 4.** Ripk3 signaling promotes low-dose IR-induced HSC elimination in an Mlkl-dependent manner

(A and B) WT, Ripk3–/–/C0–/–, and Mlkl–/–/C0–/– mice were irradiated with 6 Gy X-ray. BM MNCs were collected 2 and 48 h after IR. DNA damage was examined in LSK cells by γ-H2AX staining followed by flow cytometry (A) and microscopic analysis (B).

(C and D) WT, Ripk3–/–/C0–/–, and Mlkl–/–/C0–/– mice were irradiated with 1.75 Gy X-ray weekly × 4. BM MNCs were collected from the mice 1 month following the last IR. HSCs and HPCs were analyzed by flow cytometry gating on LSK and LK populations. Representative flow cytometric data (C) and absolute numbers of HSCs and HPCs (D) in the BM of the indicated genotypes of mice are presented. Five mice were studied in each group. *p < 0.05 compared with Ripk3–/–/C0–/– or Mlkl–/–/C0–/– groups.

(E–H) WT and Ripk3–/– mice were irradiated with X-rays, 1.75 Gy, every week for a maximum of 4 weeks. BM and PB were collected from the mice at the indicated times after the first IR. Ripk3–Mlkl signaling in BM MNC and LSK populations from WT mice was examined at the indicated times after the first IR by western blotting (E) and flow cytometry (F), respectively. Data in (F) show one of the three biological triplicate experiments, and LSK cells from Ripk3–/– mice were always studied in parallel as controls. Levels of Tnf-α in PB were examined by ELISA (G). HSC numbers/two hindlegs were examined by flow cytometric analysis (H).

(I) WT and Tnfr1–/– mice were irradiated with 1.75 Gy X-ray weekly × 4. Mice were monitored for leukemia development. Survival curves for the mice were plotted by Kaplan-Meier graphing. *p < 0.05 and **p < 0.01, compared with non-irradiated WT mice or D0 group. &p < 0.05, compared with irradiated Ripk3–/– or Mlkl–/–/C0–/– mice. In (G), **p < 0.01 compared with days 0, 1, and 7.
Taken together, these studies suggested that Ripk3 signaling in HSCs is primarily stimulated by the inflammatory cytokine Tnf-α during fractionated low-dose IR exposures. Nevertheless, enhanced T-ALL development was observed only in Ripk3−/− mice and not in Mlkl−/− mice, suggesting that the tumor-repressive activity of Ripk3 is primarily independent of Mlkl-mediated HSC elimination.

Low-dosage IR promotes Tnf-α-induced protein synthesis in HSCs in a Ripk3-dependent but Mlkl-independent manner

To study the Mlkl-independent tumor-repressive mechanism of Ripk3 signaling, we compared gene expression profiles among LK and LSK cells isolated from WT and Ripk3−/− mice 1 month after the fourth in a series of IRs using RNA-sequencing (RNA-seq) assay. We found that 86 genes showed ≥2-fold change (upregulation of 23 genes and downregulation of 63 genes) in Ripk3−/− LK cells compared with WT LK cells, while 172 genes showed ≥2-fold change (upregulation of 69 genes and downregulation of 103 genes) in Ripk3−/− LSK cells compared with WT LSK cells (Figures 5A and 5B). Gene Ontology (GO) enrichment analysis demonstrated that the altered pathways in LK cells were primarily involved in TNF/LPS-stimulated NF-κB and MAPK signaling, while the pathways altered in LSK cells were mainly involved in ribosomal and mRNA splice signaling (Figures 5C and 5D). qRT-PCR assay demonstrated that gene expression changes in LSKs and LKs isolated from Mlkl−/− mice were similar to those in the corresponding type of cells from WT and Ripk3−/− mice (Figure 5E). Consistent with this observation, we found an increased rate of protein synthesis in LSK-HSPCs isolated from IR WT and Mlkl−/− mice but not in LSK-HSPCs from Tnf1−/− mice (Figure 4I).
isolated from irradiated Tnfr−/− and Ripk3−/− mice as determined by OP-puro label assay; however, the protein synthesis rates in LK-MPs from all four genotypes of mice were comparable (Figure 5F). In addition, we found increased inflammasome activity in LK-MPs isolated from irradiated WT and Mlkl−/− mice compared with LK-MPs isolated from irradiated Tnfr−/− and Ripk3−/− mice, as demonstrated by increased activated Caspase 1 (a-Casp1) (Figure 5G); however, inflammasome activity in LSK-HSPCs from all four genotypes of mice was not altered (Figure 5G). This suggests that HSPCs and MPs have distinct responses to Tnf-α-stimulated Ripk3 signaling resulting from low-dose IR. Maintaining a low level of protein synthesis in HSCs is critical for preserving their self-renewal and hematopoietic reconstitutive capacities (Hidalgo San Jose et al., 2020; Signer et al., 2014). As a consequence, we detected increased senescence in both WT and Mlkl−/− HSCs compared with Ripk3−/− and Tnfr−/− HSCs as determined by both β-gal staining (Figure 5H) and p16/p19 expression (Figure 5I). Thus we speculate that Ripk3 mediates a Tnf-α-stimulated tumor-repressing activity through induction of protein synthesis and cellular senescence in HSCs.

Low-dose IR impairs mitochondrial-integrated stress response (ISR) in HSCs in a Ripk3-dependent but Mlkl-independent manner

The rate of protein synthesis in HSCs is restricted by eIF2a-Atf4 pathway-mediated OXPHOS and attenuating mitochondrial ISR. To study whether the increased protein synthesis observed in WT and Mlkl−/− HSCs is due to the attenuation of the eIF2-Atf4 ISR pathway, we compared the activity of the eIF2-Atf4 signaling among LSK and LK cells isolated from WT, Ripk3−/−, Mlkl−/−, and Tnfr−/− mice before and after 4× IR. We found that, prior to IR, the activity of the eIF2-Atf4 signaling in LSK cells compared with LK cells isolated from all four genotypes of mice was not different (Figure 6A and 6B). No difference was observed among the four genotypes of mice. However, after 4× IR, the activity of eIF2-Atf4 signaling was higher in LSK cells compared with LK cells isolated from all four genotypes of mice, as determined by increased levels of p-eIF2a and elevated expression of Atf4 target genes (Figures 6C–E). The activity of Perk-ER stress signaling was examined by p-Perk levels (Figure 6F). The activity of OMA1 was examined by western blotting for OPA cleavage (Figure 6G); OXPHOS was examined by OCR (Figure 6H); and mitochondrial mass and mtROS were examined by MitoTracker green staining (Figure 6I) and MitoSOX red staining (Figure 6J). Data in (A), (C), (F), (I), and (J) show one of the three biological triplicate experiments. **p < 0.01 compared with LK in (A) or WT and Mlkl−/− mice.

Stem Cell Reports j Vol. 17 j 1428–1441 j June 14, 2022 1435
IR, such activity was induced in LSK cells isolated from Ripk3−/− and Tnfr−/− mice, but was not altered in LSK cells isolated from WT and Mlkl−/− mice (Figures 6C–6E). No change was observed in LK cells from any of the genotypes of mice (Figure S6).

Four eIF2α kinases, GCN2, PERK, PKR, and HRI, can phosphorylate eIF2α and activate eIF2α-Atf4-ISR signaling. GCN2 is stimulated by amino acid depletion and PKR is activated by double-stranded RNA during viral infection. However, basal levels of eIF2α phosphorylation are primarily controlled by either endoplasmic reticulum (ER) stress-related PERK or mitochondrial stress-related HRI signaling (Fessler et al., 2020; van Galen et al., 2018). We found that there is no difference in PERK signaling among our four genotypes of LSK cells, as demonstrated by comparable levels of p-Perk (Figure 6F) and the expression of Grp78, an indicator of ER stress (data not shown). Thus we investigated whether the attenuated eIF2α-Atf4 ISR signaling in WT and Mlkl−/− HSCs is due to the failure of the OMA1–DELE1–HRI-mediated mitochondrial stress response (Fessler et al., 2020). In this pathway, DELE1 is localized to the inner membrane of mitochondria and is cleaved by active OMA1. The cleaved DELE1 is then released into the cytoplasm, where it activates HRI (Fessler et al., 2020). Due to the lack of antibodies to directly detect DELE1 and active HRI, we examined OMA1 activity by detecting the cleavage of the dynamin-like GTPase OPA1, a well-known OMA1 substrate. OMA1 is constitutively active in HSCs (van Galen et al., 2018). We found a significant reduction of OMA1 activity in WT and Mlkl−/− HSCs compared with Ripk3−/− and Tnfr−/− HSCs as determined by a reduction in the s-OPA1/l-OPA1 ratio (Figure 6G).

Pyruvate dehydrogenase complex (Pdc) is the rate-limiting enzyme that converts pyruvate to acetyl-CoA, linking glycolysis to aerobic respiration (Hitosugi et al., 2011; Kaplon et al., 2013). Tnf-α induces Ripk3-dependent aerobic mitochondrial metabolism, oxidative phosphorylation (OXPHOS), and ROS production in many types of cells by stimulating the Ripk3-mediated phosphorylation of Pdc-E3, a key subunit of Pdc (Qiu et al., 2018; Yang et al., 2018a, b). Pdc has been described as a key mediator of oncogene-induced senescence, a vital pathophysiological mechanism that protects against cancer (Kaplon et al., 2013). We found increased OXPHOS in WT and Mlkl−/− HSCs compared with Ripk3−/− and Tnfr−/− HSCs, as determined by increased oxygen consumption rate (OCR) (Figure 6H), which was associated with increased mitochondrial mass and mitochondrial ROS (mtROS), as demonstrated by MitoTracker green and MitoSOX red staining (Figures 6l and 6j).

To study whether the impaired eIF2α-Atf4 ISR signaling in WT and Mlkl−/− HSCs was due to increased Pdh-OXPHOS-mtROS, we treated irradiated mice with either the Pdh inhibitor CPI-613 or the ROS scavenger N-acetyl-L-cysteine (NAC). We found that either CPI-613 or NAC treatment could inhibit OXPHOS and mtROS and restore OPA1 cleavage and eIF2α-Atf4 signaling in both WT (Figures 7A–7E) and Mlkl−/− HSCs (Figures 7A and 7B). As a consequence, protein synthesis and senescence were repressed in both WT (Figures 7F and 7G) and Mlkl−/− HSCs (Figures S7C and S7D). Finally, CPI-613 treatment also promotes the development of T-ALL/lymphomas in WT mice (Figure 7H). In the CPI-613 treatment group, 1/12 mice died of T-ALL and 4/12 mice died of a mixture of T-ALL/thymoma within 240 days, while the remaining mice died of thymoma within 450 days. However, in the vehicle-treated group, only 5/11 mice died of thymoma within 500 days.

DISCUSSION

Ripk3-mediated necroptosis is a hallmark feature of cellular clearance of infection and plays a key role in immunity and inflammation. Abnormal activation of Ripk3 signaling is involved in many aging-related diseases, such as atherosclerosis, stroke, and leukemia. In this study, we describe a novel and HSC-specific function for Ripk3 signaling in stress hematopoiesis. We found that Ripk3 signaling was not activated in HSCs during normal homeostasis but was induced during stress hematopoiesis, such as serial transplantation and fractionated low-dose exposure to IR. Such stresses induced a delayed chronic activation of Ripk3-Mlkl signaling, which selectively regulated both the quantity of HSCs by stimulating Mlkl-dependent necroptosis and the quality of HSCs by triggering Mlkl-independent senescence.

We found that the delayed chronic activation of Ripk3-Mlkl signaling in HSCs during serial transplantation or fractionated low-dose IR exposure was largely induced by Tnf-α. Early studies suggested that Tnf-α treatment represses IR-induced leukemia by inhibiting pre-LSCs (Boniver et al., 1989; Humblet et al., 1996). However, the underlying molecular mechanism to explain this is still unknown. A recent study suggested that Tnf-α selectively regulates HSC numbers during inflammation by means of Ripk3-Mlkl-mediated necroptosis (Yamashita and Passegue, 2019). We found that, during both serial transplantation and IR exposure, in addition to inducing Mlkl-necroptosis, thus reducing the number of HSCs, Tnf-α attenuates HSC functioning and represses IR-induced leukemia development primarily by stimulating Ripk3 signaling-mediated Mlkl-independent senescence. Thus we believe that during the early pre-leukemic stage, induced activation of Ripk3 signaling might be a useful strategy to repress subsequent leukemic transformation.
Sublethal IR exposure induces p53-dependent cell-cycle arrest/senescence in HSCs (Domen et al., 1998; Wang et al., 2006). Sustained impairment of HSCs is the cause of LT-RD, which is associated with increased biomarkers of cellular senescence and a prolonged elevation of p21<sup>Cip1/Waf1</sup>, p19<sup>Arf</sup>, and p16<sup>Ink4a</sup> expression. However, deletion of both <i>p19Arf</i> and <i>p16Ink4a</i> genes failed to prevent senescence in HSCs, suggesting that p21<sup>Cip1/Waf1</sup> may play an important role in the senescence of HSCs following sublethal doses of IR (Shao et al., 2014). It was reported that Ripk3 signaling stimulates mtROS production by enhancing aerobic metabolism and respiration and attenuating mitochondrial ISR (van Galen et al., 2018; Yang et al., 2018b). We found that during fractionated low-dose IR exposure, Tnf-α-Ripk3 signaling stimulates PDC-mediated aerobic respiration and mtROS production and attenuates mitochondrial ISR, leading to increased protein synthesis and cellular senescence in pre-LSCs. Whether such Ripk3 signaling-mediated senescence in HSCs is also p53 dependent remains to be determined.

HSCs and HPCs do not respond to IR treatment in the same way (Milyavsky et al., 2010). A sublethal dose of IR (6.0–6.5 Gy) selectively kills proliferative HPCs by activating p53/Puma-mediated apoptosis but causes cell-cycle arrest and senescence in HSCs (Domen et al., 1998; Wang et al., 2006). IR induces the development of leukemia by inducing DNA damage in HSCs. Double-strand breakage is the most common type of DNA damage induced by IR. Unlike proliferative HPCs, which use homologous recombination, an error-proof mechanism to repair their...
HSCs. We found that IR-induced Tnf-α plays distinctly different roles in HSCs and HPCs. In RUNX1-ETO masomes, which might explain the critical role of Tnf-α in multiple human cell lines as well as murine embryonic fibroblasts (Yang et al., 2018b). Consistently, we found that IR-induced Tnf-α-Ripk3 signaling plays distinctly different roles in HSCs and HPCs. In HSCs, Tnf-α-Ripk3 signaling stimulates mitochondrial OXPHOS and attenuates ISR, which leads to increased protein synthesis and cellular senescence. However, in HPCs, Tnf-α-Ripk3 signaling stimulates the activation of inflamasomes, which might explain the critical role of Tnf-α-Ripk3-inflammasome signaling in the pathogenesis of RUNX1-ETO- or FLT3-ITD-induced AML in models (Hockendorf et al., 2016; Xin et al., 2016b). Yang et al. reported that Tnf-α-Ripk3 signaling increases mitochondrial OXPHOS by phosphorylating Pdc-E3 and activating Pdh in multiple human cell lines as well as murine embryonic fibroblasts (Yang et al., 2018b). Consistently, we found that IR-induced Tnf-α-Ripk3 signaling also stimulates Pdh activation and mitochondrial OXPHOS in HSCs. Yang’s study demonstrated that Tnf-α-Ripk3 signaling-stimulated mitochondrial OXPHOS in L929 cells is dependent upon Mlkl (Yang et al., 2018b). However we found that Mlkl is not required for the Tnf-α-Ripk3 signaling-stimulated mitochondrial OXPHOS in HSCs. We speculate that such a discrepancy might be due to differences in the way in which signaling is activated and/or the nature of the specific cell type studied.

**EXPERIMENTAL PROCEDURES**

**Mice**

Ripk3<sup>−/−</sup> mice, Mklk<sup>−/−</sup> mice, and Tnfr1<sup>−/−</sup> mice, described previously, were maintained in a C57BL/6J background (Wang et al., 2016; Xin et al., 2016b). WT C57BL/6J control mice and Ptprc recipient mice were purchased from The Jackson Laboratory (Bar Harbor, ME). All mice were maintained according to the standards in the National Institutes of Health Guidelines for the Care and Use of Animals in the AAALAC-certified pathogen-free animal facility at Loyola University Medical Center. All mice were housed under a 12-h light/dark cycle in microisolator cages contained within a laminar flow system. All procedures were conducted in accordance with the National Institutes of Health guidelines for the care and use of laboratory animals for research purposes and were approved in advance by the Loyola University Chicago IACUC (2017-038). Genotypes of the mice were determined by PCR assay. The PCR primer sequences for genotyping can be found in Table S1.

**Mouse irradiation and treatments**

Mice were exposed to various doses of IR in an RS 2000 biological research X-ray irradiator (Rad Source Technologies) at a rate of 1.17 Gy/min. Mice were irradiated in a specifically designed mouse cage, four mice per cage. After radiation, all mice were housed in a germ-free facility and provided with drinking water containing 0.16 mg/mL Baytril for 2 weeks to prevent bacterial infection.

To study IR-induced leukemia development, mice were treated with 1.75 Gy × 4 IR and monitored for leukemia development. Survival curves of mice were calculated by Kaplan-Meier estimation. The PDC inhibitor CPI-613 was purchased from InvivoChem (V083S), dissolved in 1% DMSO/30% polyethylene glycol/1% Tween 80, and administered intraperitoneally (i.p.), 20 mg/kg, every other day for 3 weeks. NAC was purchased from Sigma-Aldrich and administered at 200 mg/kg daily for 3 consecutive weeks. The p38 MAPK inhibitor SB 203580 was purchased from AdooQ, dissolved in PEG 400/0.5% Tween 80/5% propylene glycol, and administered at a dosage of 5 mg/kg/daily i.p.

**Mouse hematopoietic phenotype analysis**

Mice were sacrificed at the indicated time points to collect PB, spleens, thymuses, and BM. PB was analyzed for WBC counts, Plt, RBC counts, and Hb concentration using a Hemavet 950FS (Drew Scientific). After lysis of RBCs, MNCs from PB, spleens, thymuses, and BM were counted and further stained with cell surface markers for phenotypic analysis using flow cytometry as described previously (Tang et al., 2008; Xiao et al., 2011). All of the fluorescent antibodies used in flow cytometric analyses were purchased from either eBioscience or Biolegend. For HSC and HPC analysis, 1 × 10<sup>6</sup> BM MNCs were incubated with BV421-conjugated antibodies against lineage<sup>+</sup> cells (including CD3ε, B220, Gr-1, CD11b, and Ter-119), anti-Sca-1-PE, anti-c-kit-APC, anti-CD48-APCcy7, anti-CD150-PEcy7, anti-CD150-PECy7, anti-CD127-Alex 710, anti-CD34-Alex 710, and anti-CD16/32-FITC antibodies. For each sample, a minimum of 300,000 cells was collected on a Fortessa flow cytometer (Fortessa, Becton Dickinson) and the data were analyzed using FlowJo software (FlowJo) after gating on viable single cells.

**Isolation of HSCs, MPPs, LSKs, and LK-MPs**

BM-MNCs were collected from mice. Lin<sup>−</sup> cells were enriched using the MojoSort mouse hematopoietic progenitor cell isolation kit (Biolegend cat. no. 480004) following the protocol provided by the vendor. Lin<sup>−</sup> cells were then stained with a BV421-conjugated cocktail of anti-lineage antibodies (mixture of anti-Gr1-BV421, anti-CD11b-BV421, anti-CD3-BV421, anti-B220-BV421, and anti-Ter119-BV421), anti-Sca-1-PE, anti-c-kit-APC, anti-CD150-PEcy7,
anti-CD 48-APCcy7, and anti-CD135-Alex 710 after pre-incubation with anti-CD16/32 to block the Fcγ receptors. After being washed, the cells were resuspended in PBS and sorted using a BD FACSaria III sorter (Becton Dickinson, San Jose, CA).

**Real-time RT-PCR analysis**

Total RNA was isolated from HSCs and MPP, LSK, and LK cells using TRIzol reagent (Invitrogen, Carlsbad, CA) following the manufacturer’s protocol. cDNA was generated from RNA using SuperScript III reverse transcriptase (Life Technologies). Levels of mRNA of the genes of interest were examined by qRT-PCR using the TaqMan assay (Thermo Fisher Scientific) following the instructions provided by the vendor. Gapdh was used as a control. The primers for qRT-PCR used in this study are listed in Table S2. The threshold cycle values (CT) for each reaction were determined and averaged using TaqMan SDS analysis software (Applied Biosystems). The changes in target gene expression were calculated by the comparative CT method (fold change = 2^{-\Delta\Delta CT}), as described previously. Each sample was a mixture of LSK HSCs from three mice of the same phenotype. Triplicate RT-PCRs were performed.

**Statistical analyses**

Data are expressed as the mean ± SD. Two-way ANOVA (multiple groups) and Student’s t test (two groups) were performed to determine the statistical significance of differences among and between experimental groups. A p < 0.05 was considered significant. All analyses were done using GraphPad Prism from GraphPad Software (San Diego, CA).

**Data and code availability**

The RNA-seq dataset was deposited into the Gene Expression Omnibus archive (accession no. GSE70899 and GEO no. GSE139143).

**SUPPLEMENTAL INFORMATION**

Supplemental information can be found online at https://doi.org/10.1016/j.stemcr.2022.04.009.

**AUTHOR CONTRIBUTIONS**

L.Z., H.L., H-M.N., S.L., H.X., M.S., Jun Zhang, W.W., and P.B. performed the research experiments and analyzed the data. P.B., M.D., W.S., W.D., S.H., and Jiwang Zhang analyzed the data and wrote the paper. Jiwang Zhang designed and performed the research, analyzed the data, and wrote the paper. P.B. revised and edited the paper.

**CONFLICTS OF INTEREST**

The authors declare no competing interests.

**ACKNOWLEDGMENTS**

The authors thank the staff of the Department of Comparative Medicine at Loyola University Medical Center for their excellent animal care services, as well as Ms. Patricia Simms for flow cytometric sorting of HSCs and progenitors. This work was supported by NIH grants NHLBI R01 HL133560 and NCI R01 CA223194 through Loyola University Chicago and NIAAA R01 AA020518 and U01 AA024733 through Kansas University Medical Center. It was also supported by Loyola Program Development funding to Jiwang Zhang.

Received: September 7, 2021
Revised: April 14, 2022
Accepted: April 14, 2022
Published: May 12, 2022

**REFERENCES**


